Some OPEC members are in a lot worse shape then the US oil and gas producers.
I have worked in biotech (now retired) and I think that 1456 has the potential to be a blockbuster. However, nothing is sure.
I believe that OPEC only has twelve members. It only takes a majority ( 7 )to call a meeting. There should be enough votes to do it. Sticking to new quotas is a more difficult matter.
I think it's something like $33 or 18 billion. Big oil which is still making a profit would find that buying this company would save them billons in US taxes. Maybe the CVX rumor is actually true.
Every molecule in an ADC requires a humanized antibody. These are difficult and expensive to make. The ECYT products use folic acid ( vitamin B9), a commercially available molecule that can be bought by the pound for a reasonable price. The sleeper improvement in going from 145 to 1456 is changing the linker to be more water soluble so the drug is eliminated by the kidneys not the liver. This is a good stock for people who like to gamble.
Keep your eye on this stock
Almost all ADC's on the market or in development come with a companion imaging agent. None has been mentioned so far for IMMU 132 or 130. Pretesting with the imaging agent is done to determine if the tumor overexpresses the surface receptor that the antibody targets. Only those patients whose tumor expresses the targeted surface protein are good candidates for the drug. The FDA will probably raise the subject. Most imaging agents are made by binding Tc99 to the antibody ( Trop2, or Ceacam ).
I saw the U. Chicago paper in 2012. The university holds the patent rights on Relistor and PROG has to pay a fee to the university on any sales .Also, the university still has the rights for use as a cancer drug.